With the PDUFA date for its capsaicin pain patch Qutenza (capsaicin 179 mg) rapidly approaching, NeurogesX Inc. gained a nice chunk of cash and squared away European rights to the product in a potential €105 million (US$145.5 million) deal with Astellas Pharma Inc. (BioWorld Today) Read More